Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2015 Mar 25;6:58. doi: 10.3389/fphar.2015.00058

New perspectives in signaling mediated by receptors coupled to stimulatory G protein: the emerging significance of cAMP efflux and extracellular cAMP-adenosine pathway

Rosely O Godinho 1,*, Thiago Duarte 1, Enio S A Pacini 1
PMCID: PMC4373373  PMID: 25859216

Abstract

G protein-coupled receptors (GPCRs) linked to stimulatory G (Gs) proteins (GsPCRs) mediate increases in intracellular cyclic AMP as consequence of activation of nine adenylyl cyclases , which differ considerably in their cellular distribution and activation mechanisms. Once produced, cyclic AMP may act via distinct intracellular signaling effectors such as protein kinase A and the exchange proteins activated by cAMP (Epacs). More recently, attention has been focused on the efflux of cAMP through a specific transport system named multidrug resistance proteins that belongs to the ATP-binding cassette transporter superfamily. Outside the cell, cAMP is metabolized into adenosine, which is able to activate four distinct subtypes of adenosine receptors, members of the GPCR family: A1, A2A, A2B, and A3. Taking into account that this phenomenon occurs in numerous cell types, as consequence of GsPCR activation and increment in intracellular cAMP levels, in this review, we will discuss the impact of cAMP efflux and the extracellular cAMP-adenosine pathway on the regulation of GsPCR-induced cell response.

Keywords: G protein-coupled receptors, cyclic AMP, cAMP efflux, adenosine, adenosine receptors, ABC transporters, ecto-phosphodiesterase, ecto-5′-nucleotidase

Seven transmembrane receptors are able to transmit extracellular signals into the intracellular compartment via activation of heterotrimeric G proteins, which consist of the guanine nucleotide-binding Gα subunit and the dimeric βγ subunits (Pierce et al., 2002). These G protein-coupled receptors (GPCRs) are ubiquitously distributed and precisely regulate a myriad of intracellular processes upon agonist stimulation. GPCRs may also activate β-arrestin-dependent signaling, which functions as an adaptor protein that regulates GPCR signaling and trafficking, having the ability to activate intracellular pathways independently of G proteins (DeWire et al., 2007).

The membrane-associated G proteins can be divided into four families according to the primary sequence similarity of Gα subunits: Gαs (αs, αolf), Gαi (αi1–αi3, αt, αo1–αo2, αζ), Gαq/11 (αq, α11, α14–α16), Gα12 (α12, α13). The sequence homologies also define the Gα subunit coupling to downstream effector molecules, such as phospholipase C-β, adenylyl cyclase (AC), RhoGEFs and/or ion channels (Moreira, 2014).

Conformational changes of GPCR, induced by extracellular agonist binding, reduces the affinity of GDP to Gα subunit, resulting in sequential dissociation of GDP-Gα complex, interaction of GTP with Gα, and dissociation of heterotrimeric complex Gα–βγ into Gα subunit and βγ dimmer (Pierce et al., 2002). Focusing on activation of GPCRs linked to stimulatory G (Gs) proteins (GsPCR), the GTP-Gαs complex is able to interact and activate all available membrane bound AC isoforms (AC1–AC9), increasing the intracellular generation of adenosine 3′,5′-cyclic monophosphate (3′,5′-cAMP or cAMP). Conversely, by activating inhibitory G (Gi) protein, agonists of GiPCR elicit the selective inhibition of AC1, AC5, and AC6, reducing the intracellular cAMP content(Sadana and Dessauer, 2009).

Cyclic AMP was first described by Rall et al. (1957) who showed that sympathomimetic amines and glucagon were able to induce the synthesis of a heat-stable factor formed by particulate fractions of liver homogenates in the presence of ATP and Mg2+. Identified as adenine ribonucleotide, the compound was identical to the cAMP described by Cook et al. (1957) at the same year. Since then, intracellular signaling through cAMP has been described in virtually every cell (Antoni, 2012). The protein kinase A (PKA), a serine/threonine kinase ubiquitously expressed in mammal tissues, was the first cAMP downstream target to be identified (Walsh et al., 1968). Formed by two regulatory and two catalytic subunits, activation of PKA involves the cooperative binding of four cAMP molecules to two regulatory subunits, leading the catalytic subunits free to phosphorylate target proteins. Intracellular cAMP is also able to directly modulate ion channels (Bradley et al., 2005), such as the hyperpolarization-activated cyclic nucleotide-gated channels (HCN channels) expressed in the cardiac sinoatrial node (Larsson, 2010). Additionally, exchange proteins directly activated by cAMP (Epac) explained various effects of cAMP that could not be attributed to the PKA or cAMP-gated ion channels (Gloerich and Bos, 2010).

Phosphodiesterases, MRP/ABCC Transporters and cAMP Efflux

The fine regulation of intracellular cAMP signaling is made by phosphodiesterases (PDEs), enzymes that catalyze the hydrolysis of cAMP into AMP. Actually, the superfamily of PDE enzymes is comprised of 11 families, namely PDE1–PDE11. While PDE4, PDE7, and PDE8 are specific for cAMP, PDE5–PDE6, and PDE9 are specific for guanosine 3′,5′-cyclic monophosphate (cGMP) and PDE1–PDE3 and PDE10–PDE11 hydrolyze both cAMP and cGMP (Bender and Beavo, 2006; Francis et al., 2011). By hydrolyzing the cyclic nucleotide monophosphates, PDEs regulate several important physiological processes, such as vascular resistance, cardiac output, visceral motility, immune response, inflammation, neuroplasticity, vision, and reproduction (Azevedo et al., 2014). Therefore, altered expression of PDE or changes in the enzyme activity have been associated with a number of pathological conditions, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, chronic obstructive pulmonary disease and various types of cancer (Azevedo et al., 2014).

In addition to PDE, the intracellular concentration of cAMP is regulated by its efflux into the extracellular space through a specific transport system named multidrug resistance proteins (MRP; Cheepala et al., 2013) that belongs to the ATP-binding cassette (ABC) transporter superfamily (subfamily C). Three of them (MRP4/ABCC4, MRP5/ABCC5, and MRP8/ABCC11) have the ability to actively extrude cAMP and cGMP from the cell (Kruh and Belinsky, 2003) with different kinetic parameters (Km values in the μM range; Jedlitschky et al., 2000; Chen et al., 2001; Guo et al., 2003; Sager and Ravna, 2009).

The MRP-mediated cAMP efflux has been shown in many cell types, including rodent skeletal muscle (Godinho and Costa, 2003), human platelets (Jedlitschky et al., 2004) vascular smooth muscle cells (Sassi et al., 2008; Cheng et al., 2010), pulmonary arteries (Hara et al., 2011) and cardiac myocytes (Sassi et al., 2011). Therefore, it was proposed that by working synergistically with PDE enzymes, MRP-mediated cAMP efflux would preserve the cell from excessive levels of intracellular cAMP (Jedlitschky et al., 2000; Chen et al., 2001). Although reasonable, this premise was not consistent with the high energetic cost of pumping cAMP out of cell (Godinho and Costa, 2003; Chiavegatti et al., 2008). Thus, it was hypothesized that cAMP might also function as an extracellular signaling molecule (Jackson and Raghvendra, 2004). In fact, since the middle 1960s, extracellular effects of cAMP have been reported in different mammal tissues and organs. For example, intravenous infusion of cAMP is known to produce a wide range of responses, including increased adrenal corticosterone secretion in hypophysectomized rats (Imura et al., 1965), increment in heart rate, cardiac output, and blood glucose, reduction of blood pressure (Levine and Vogel, 1966) and increment in calcium and phosphate plasma concentration (Rasmussen et al., 1968). cAMP infusion effects seem to be exclusively extracellular since most cells are impermeable to cAMP (Robison et al., 1965).

Ecto-Phosphodiesterases, Ecto-Nucleotidases, and the Extracellular cAMP-Adenosine Pathway

The idea of an extracellular role for cAMP gained strength in the late 1990s when it was established that extracellular cAMP could be sequentially metabolized into AMP and adenosine, a phenomenon named “extracellular cAMP-adenosine pathway” (Mi and Jackson, 1998). Actually, the existence of ecto-enzymes with PDE activity was first demonstrated in frog skeletal muscle by Woo and Manery (1973), who showed extracellular generation of [14C]AMP as consequence of incubation of intact posterior leg muscles with [14C]cAMP. The degradation of cAMP was markedly inhibited by theophylline, suggesting the presence of cAMP-phosphodiesterase activity at the muscle fiber surface (Woo and Manery, 1973). Later, ecto-phosphodiesterase activity was found in rodent liver cells (Smoake et al., 1981), vascular smooth muscles (Dubey et al., 1996; Jackson et al., 1997), adipocytes (Strouch et al., 2005), skeletal muscle (Chiavegatti et al., 2008), rat ileum (Giron et al., 2008), astrocytes and microglia (Verrier et al., 2011) and many other cells.

In those cells, following the extracellular degradation of 3′,5′-cAMP by ecto-PDE, 5′-AMP is rapidly hydrolyzed to adenosine by membrane-bound ecto-5′-nucleotidases (EC 3.1.3.5), also known as CD73. The ecto-5′-nucleotidase is a 70-kDa cell surface glycoprotein found in most tissues that functions as the major enzymatic source of interstitial adenosine (Colgan et al., 2006). Although ecto-5′-nucleotidases also hydrolyzes other ribo- and deoxyribonucleoside 5′-monophosphates including cytidine-, uridine-, inosine-, and guanosine-5′-monophosphates, AMP is the most effectively hydrolyzed nucleotide (Zimmermann et al., 2012). Thus, by hydrolyzing 5′-AMP derived from either ATP or cAMP, ecto-5′-nucleotidases act as a limiting point for the extracellular provision of adenosine and, as consequence, for activation of adenosine receptors (ARs).

In addition to ecto-5′-nucleotidases, other three types of surface-located ecto-nucleotidases are involved in the extracellular nucleosides degradation and, consequently, in the extracellular adenosine formation: ecto-nucleoside triphosphate diphosphohydrolases (EC 3.6.1.5), ecto-nucleotide pyrophosphatase/PDEs (EC 3.6.1.9 and EC 3.1.4.1) and alkaline phosphatases (APs; EC 3.1.3.1). While ecto-5′-nucleotidases is nucleotide-specific, ecto-nucleotide pyrophosphatase/PDEs and ecto-nucleoside triphosphate diphosphohydrolases hydrolyze both ATP and ADP (Zimmermann et al., 2012).

Adenosine Receptors and the Extracellular cAMP-Adenosine Pathway

The extracellular degradation of cAMP allows the activation of membrane associated ARs by its metabolite adenosine. Pharmacologically, four distinct subtypes of ARs, members of the GPCR family, are described: A1, A2A, A2B, and A3 (Fredholm et al., 2011). These receptors have a very broad tissue distribution, performing relevant physiological effects in central nervous system (Ribeiro et al., 2002; Wei et al., 2011), cardiovascular (Headrick et al., 2013; Idzko et al., 2014a) and musculoskeletal systems (Burnstock et al., 2013) and many other tissues (Vallon et al., 2006; Sheth et al., 2014). Activation of adenosine is also involved in pathophysiological conditions such as cancer, inflammation (Antonioli et al., 2013; Idzko et al., 2014b) and neurodegenerative diseases, with potential therapeutic implications for Parkinson’s and Alzheimer’s diseases (Ribeiro et al., 2002).

AR subtypes exhibit different affinities for the endogenous agonist (Muller and Jacobson, 2011): A1, A2A, and A3 display high to moderate affinity (Ki = 100, 310, and 290 nM, respectively) to adenosine whereas A2B has low affinity (Ki = 15 μM). Furthermore, distinct signaling transduction pathways are mobilized by each AR, leading to diverse cellular effects. The A1 and A3 are preferentially coupled to the Gi/o family of G-proteins whereas the A2A and A2B couple to Gs proteins (Trincavelli et al., 2010). Thus, as shown in Figure 1, depending on the receptor subtypes expressed in the cell, the extracellular cAMP-adenosine pathway will be able to increase (Figure 1A) or attenuate (Figure 1B) the intracellular cAMP production, by activating or inhibiting ACs, via Gs and Gi proteins, respectively. Therefore, the final biological effect of the extracellular cAMP-adenosine pathway will depend on AR subtype expressed by the target cell and on the amount of cAMP pumped out of the cell.

FIGURE 1.

FIGURE 1

Open in a new tab

Feedback mechanisms mediated by the extracellular cAMP–adenosine cascade. Activation of receptors coupled to Gs protein (GsPCR) leads to stimulation of adenylyl cyclase (AC) and increased generation of cAMP, which may elicit localized cellular response via activation of effectors such as PKA or Epac (A,B), which are organized in microdomains via anchoring proteins, such as AKAP. cAMP may be hydrolyzed by intracellular phosphodiesterases (PDEs) or may leave the cell via multidrug resistance proteins (MRPs). Outside the cell, ecto-PDE and ecto-5′nucleotidase sequentially convert cAMP to AMP and adenosine (ADO), which may activate Gs-coupled A2A/A2B (A) or Gi-coupled A1/A3 (B) receptors, increasing or attenuating cAMP production, respectively. In addition, activation of receptors coupled to Gi protein (GiPCR) results in inhibition of Gi-sensitive ACs reducing both generation and efflux of cAMP (C), with consequent loss of autocrine/paracrine feedback signaling of extracellular cAMP.

In fact, the extracellular cAMP-adenosine signaling can be even more complex, as in addition to classical Gs and Gi pathways, AR subtypes can also activate Gq protein (A2B and A3), phospholipase C-β (A1, A2B, and A3), PKC (A2B and A3), KATP channel (A3), and ERK1/2 (A1, A2A/A2B, and A3) p38 (A1 and A2B) MAPK cascade (Feoktistov et al., 1999; Schulte and Fredholm, 2003), which in turn are able to modulate AC activation (Sadana and Dessauer, 2009).

Activation of GsPCR and the Extracellular cAMP-Adenosine Pathway

Taking into account that cAMP may function as an extracellular signaling molecule, it is possible to assume that, by stimulating AC enzymes, all GsPCRs may have significant impact on cAMP efflux and extracellular cAMP-adenosine signaling. Actually, by studying the contribution of cAMP efflux and the extracellular cAMP-adenosine pathway on skeletal muscle physiology, we showed that cAMP egress induced by activation of GsPCR, such as β-adrenoceptors and calcitonin gene-related peptide receptors, is proportional to intracellular levels of cAMP produced (Godinho and Costa, 2003; Chiavegatti et al., 2008). Of more importance, cAMP efflux and subsequent extracellular generation of adenosine elicited by β2-adrenoceptor agonists results in a delayed attenuation of β2-adrenoceptor-induced positive inotropic effect, via activation of A1 ARs (Duarte et al., 2012), as schematically shown in Figure 1B.

The correlation of GsPCR activation, cAMP efflux, and the extracellular cAMP-adenosine pathway has been described in many other cells. For example, the β-adrenoceptor agonist isoproterenol stimulates cAMP secretion from rat cultured glioma cells (Doore et al., 1975) and turkey erythrocytes (Rindler et al., 1978). In mouse adrenocortical tumor cell line, the intracellular cAMP formed in response to ACTH appeared extracellularly in few minutes (Schimmer and Zimmerman, 1976). In healthy volunteers, infusion of glucagon after hepatic venous catheterization was associated with a marked increase in both the splanchnic cAMP production and in the arterial cyclic nucleotide levels (Grill et al., 1979). In addition, while activation of D1 dopamine receptor stimulates cAMP efflux from rat neostriatal cells (Plantie et al., 1983), vasoactive intestinal peptide and cholecystokinin-8 cause a significant increase in cAMP efflux from rat striatal slices (O’Shaughnessy et al., 1987). Many other GsPCR agonists are able to stimulate cAMP efflux, such as corticotropin-releasing hormone and melanocortin (de Koning et al., 1992), vasopressin (Tyagi et al., 1998) and pituitary AC activating polypeptide (Cui et al., 2000). Taking into account that cAMP efflux depends on increased intracellular generation of cyclic nucleotide it is possible to presume that cAMP export could be ubiquitously elicited by activation of every GsPCR.

Conversely, it is also plausible to postulate that by inhibiting Gαi-sensitive ACs and reducing intracellular cAMP generation, receptors linked to Gi protein (GiPCR) would be able to negatively modulate cAMP efflux. For instance, cAMP egress from rat neostriatal slices induced by activation of Gs-linked D-1 dopamine receptors is reduced by agonists of D2 receptor agonists (Stoof and Kebabian, 1981), μ- or δ opioid receptors (Schoffelmeer et al., 1985) and M2 and M4 muscarinic receptors (Schoffelmeer et al., 1988), known to be coupled to Gi-protein. Indeed, several pheromones and fatty acids, components of membrane phospholipids, also inhibit cAMP export (Kanter et al., 1989) by activating free fatty acid receptors, such as FFA5, linked to Gi/o protein (Wang et al., 2006). Thus, inhibition of cAMP egress as consequence of inhibition of cAMP production may provide an additional mechanism by which GiPCR agonists influence the cAMP signaling pathway, as illustrated in Figure 1C. Table 1 presents a list of GPCR receptors linked to Gs and Gi protein (Alexander et al., 2013) that, by modulating intracellular generation of cAMP, may function as regulators of cAMP efflux and extracellular cAMP adenosine pathway.

Table 1.

Receptors coupled to stimulatory (Gs) and inhibitory (Gi) G proteins th

Gα subunits
Receptors coupled to inhibitory G protein (Gαi)
Orphans: GPR22, GPR34, GPR37, GPR84,1 MRGPRD, GPR33, GPR37L1, OPN5 Hydroxycarboxylic acid: HCA1, HCA2, HCA3
Acetylcholine (Muscarinic): M2, M4 5-Hydroxytryptamine: 5-HT1A, 5-HT1B, 5-HT1D–5-HT1F, 5-Ht5A
Adenosine: A1, A3 Leukotriene/lipoxin/oxoeicosanoids: BLT1–BLT2, FPR2/ALX, OXE
Adrenoceptor (α): α2A, α2B, α2C Lysophospholipid (LPA): LPA1–LPA4
Angiotensin: AT2 Sphingosine 1-phosphate (S1P): S1P1, S1P3–S1P5
Apelin: HGNC Melanin-concentrating hormone (MCH): MCH1
Calcium sensing: CaS Melatonin: MT1–MT2
Cannabinoid: CB1, CB2 Metabotropic glutamate (mGlu): mGlu2–mGlu4; mGlu6–mGlu8
Chemokine: CCR1–CCR10, CXCR1–CXCR6, CX3CR1, XCR1 Neuropeptide FF/neuropeptide AF: NPFF2
Complement peptide: C3a, C5a1 Neuropeptide W/neuropeptide B: NPBW1–NPBW2
Dopamine: D2, D3, D4 Neuropeptide Y: Y1–Y2, Y4–Y6
Endothelin: ETB Opioid: δ, κ, μ, NOP
Estrogen (G protein-coupled): GPER Purinergic P2Y: P2Y12–P2Y13
Formylpeptide: FPR1, FPR2/ALX Peptide P518: QRFP
Free fatty acid: FFA3, FFA2, FFA5 Platelet-activating factor: PAF
Gaba: GabaB Prostanoid: DP2, EP3
Galanin: GAL1, GAL2, GAL3 Proteinase-activated (PARs): PAR1, PAR2, PAR4
Glycoprotein hormone: TSH, LH Relaxin family peptide (RXFP): RXFP3–RXFP4
GPR18 (provisional nomenclature) Somatostatin (sst): sst1–sst5
Histamine: H3, H4 Vasopressin and Oxytocin: OT
Receptors coupled to stimulatory G protein (Gαs)
Orphans: GPR3-GPR4, GPR6, GPR26, GPR61, GPR65, GPR132, TAAR2, GPR78, GPR174 Histamine: H2
5-Hydroxytryptamine: 5-HT4, 5-HT6–5-HT7 Lysophospholipid (LPA): LPA3-LPA4
Adenosine: A2A, A2B Sphingosine 1-phosphate (S1P): S1P2–S1P4
Adrenoceptor (β): β1–β3 Melanocortin: MC1–MC5
Bile acid Neuropeptide S: NPS
Calcitonin: CGRP, AM1–AM2, CT, AMY1–AMY3, Purinergic P2Y: P2Y11
Cholecystokinin: CCK1, CCK2 Parathyroid hormone: PTH1–PTH2
Corticotropin-releasing factor: CRF1, CRF2 Prostanoid: DP1, EP2, EP4
Dopamine: D1, D5 Relaxin family peptide (RXFP): RXFP1–RXFP2
Endothelin: ETA Trace Amino: TA1
Estrogen (G protein-coupled): GPER Vasopressin and Oxytocin receptors: V2
Glucagon: glucagon, GLP-1–GLP-2, GIP, GHRH, secretin Vasoactive intestinal peptide and PACAP: VPAC1, VPAC2, PAC1
Glycoprotein hormone: FSH, LH
Open in a new tab

Assuming the physiological significance of cAMP efflux and extracellular cAMP-adenosine pathway in modulating GsPCR signaling, impairment of this extracellular feedback mechanism may have profound impact in several physiological processes leading to pathological conditions associated to cardiovascular, muscular and endocrine disorders and/or inflammatory diseases. For example, cAMP secreted from cardiomyocytes attenuates the development of hypertrophy and fibrosis induced by continuous activation of β2-adrenoceptors (Sassi et al., 2014). Similarly, cAMP efflux induced by prolong stimulation of β2-adrenoceptors attenuates skeletal muscle contraction, preserving muscle from deleterious effects of massive Ca2+ release from the sarcoplasmic reticulum (Duarte et al., 2012). In pancreatic acinar cells, cAMP egression through MRP4 clearly attenuates the development of acute pancreatitis induced by caerulein (Ventimiglia et al., 2015). On the other hand, inhibition of cAMP efflux with probenecid reduces bovine sperm capacitation (Osycka-Salut et al., 2014). Finally, the extracellular cAMP-adenosine pathway is able to exert immunoregulatory effects by modulating monocyte function and differentiation through A2A/A2B receptors (Sciaraffia et al., 2014), which is consistent with the marked reduction of ecto-5′-nucleotidases expression in lymphocytes from patients with a variety of immunodeficiency diseases (Resta et al., 1998). Interestingly, certain antioxidants derived from plants such as the flavonoid quercetin, have been found to inhibit cAMP efflux transporters (Pavan et al., 2015), which open new perspectives in the use of natural products as regulators of extracellular cAMP signaling for therapeutic purposes.

cAMP Signaling Microdomains

The compartmentalized expression of cAMP signaling components such as GPCR, AC, PKA, and Epacs (Laflamme and Becker, 1999; Zaccolo, 2009; Terrin et al., 2012) allows the establishment of multiple intracellular cAMP subcompartments. For example, PDEs bind to A kinase-anchoring proteins (AKAPs) forming a PKA-PDE-AKAP complex (Stangherlin and Zaccolo, 2011; Terrin et al., 2012). Likewise, specific AC isoforms have been identified as components of AKAP complexes (Dessauer, 2009), contributing to intracellular compartmentalization of cAMP signaling. In fact, localized expression of ACs generate specific microdomains of elevated concentration of cAMP ensuring signaling specificity, such as those observed in the transverse tubule/junctional sarcoplasmic reticulum network of cardiac and skeletal muscle (Gao et al., 1997; Zaccolo et al., 2002; Menezes-Rodrigues et al., 2013).

Interestingly, the localized expression of MRPs may also play an important role in the intra- and extracellular cAMP signaling process (Cheepala et al., 2013). For example, in the gut epithelia signal compartmentalization of cAMP with MRP4 is essential for cAMP-dependent regulation of chloride channel function (Li et al., 2007). As well, contraction of cardiac myocytes induced by activation of β-adrenoceptor/AC/cAMP cascade can be locally regulated by MRP4 (Sellers et al., 2012). In addition, in vascular smooth muscle cells, MRP4 was found in caveolin-rich membrane fractions regulating cAMP/PKA/CREB pathway cascade (Sassi et al., 2008). Thus, multiprotein signaling complexes, which include MRPs may affect the final GsPCR/cAMP-dependent cellular response. Of more importance, the compartmentalized expression of ARs in caveolae/cholesterol-rich microdomains (Sitaraman et al., 2002; Cordeaux et al., 2008; Garg et al., 2009; Assaife-Lopes et al., 2010) suggests that colocalization of MRP4 and ARs in caveolae microdomains coordinates the cAMP efflux in the vicinity of the AR domain (Xie et al., 2011; D’ Ambrosi and Volonte, 2013).

On the other hand, activation of ARs involved in the extracellular cAMP-adenosine pathway also depends on the availability and distribution of the ecto-enzymes. Ecto-phosphodiesterase and ecto-nucleotidases or adenosine deaminase can very rapidly modulate the extracellular concentrations of adenosine, which will directly affect receptor subtype activation, and as consequence, the final cell response. Interestingly, while all human AR subtypes contain the caveolin binding domain (Mundell and Kelly, 2011), studies analyzing the subcellular distribution of A1 receptors on cardiomyocytes showed that selective activation of A1 receptors with CCPA results in the switch of A1 receptor from caveolin-3-enriched domains to the bulk plasma membrane (Lasley, 2011). The lipid raft localization of A1 receptor seems to be essential for the A1-dependent activation of KATP channels that is involved in cardioprotective effects of adenosine. Disruption of cholesterol-rich microdomains with methyl-cyclodextrin drastically reduces the effect of ARs on rat ventricular myocytes KATP channels (Garg et al., 2009; D’ Ambrosi and Volonte, 2013).

Conclusion

The existence of a system involved in sequential extrusion and extracellular degradation of cAMP definitively extend the intracellular signaling relevance of cAMP to an extracellular level, which allows paracrine and/or autocrine feedback signaling, depending on the AR subtype expressed on the target and neighboring cells. In view of the recognized ability of adenosine to regulate many cellular processes (Burnstock, 2007), the existence of the extracellular cAMP-adenosine reveals new insights into the regulatory mechanisms of cellular response triggered by GsPCR and provides novel therapeutic targets for treatment of a number of diseases associated with dysfunction of GPCR signaling cascade.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank Dr. Marcelo Funke and Fernanda Eloi for helpful comments on the manuscript. This work was supported by Fapesp (2011/01519-4; 2012/20148-0) and CNPq to RG, TD, and EP are Ph.D fellow from Capes and CNPq.

References

  1. Alexander S. P., Benson H. E., Faccenda E., Pawson A. J., Sharman J. L., Spedding M., et al. (2013). The Concise guide to PHARMACOLOGY 2013/14: g protein-coupled receptors. Br. J. Pharmacol. 170 1459–1581. 10.1111/bph.12445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antoni F. A. (2012). New paradigms in cAMP signalling. Mol. Cell. Endocrinol. 353 3–9. 10.1016/j.mce.2011.10.034 [DOI] [PubMed] [Google Scholar]
  3. Antonioli L., Blandizzi C., Pacher P., Hasko G. (2013). Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13 842–857. 10.1038/nrc3613 [DOI] [PubMed] [Google Scholar]
  4. Assaife-Lopes N., Sousa V. C., Pereira D. B., Ribeiro J. A., Chao M. V., Sebastiao A. M. (2010). Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: implications for neuromodulation. J. Neurosci. 30 8468–8480. 10.1523/JNEUROSCI.5695-09.2010 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  5. Azevedo M. F., Faucz F. R., Bimpaki E., Horvath A., Levy I., de Alexandre R. B., et al. (2014). Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr. Rev. 35 195–233. 10.1210/er.2013-1053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bender A. T., Beavo J. A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 488–520. 10.1124/pr.58.3.5 [DOI] [PubMed] [Google Scholar]
  7. Bradley J., Reisert J., Frings S. (2005). Regulation of cyclic nucleotide-gated channels. Curr. Opin. Neurobiol. 15 343–349. 10.1016/j.conb.2005.05.014 [DOI] [PubMed] [Google Scholar]
  8. Burnstock G. (2007). Purine and pyrimidine receptors. Cell. Mol. Life Sci. 64 1471–1483. 10.1007/s00018-007-6497-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burnstock G., Arnett T. R., Orriss I. R. (2013). Purinergic signalling in the musculoskeletal system. Purinergic Signal. 9 541–572. 10.1007/s11302-013-9381-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cheepala S., Hulot J. S., Morgan J. A., Sassi Y., Zhang W., Naren A. P., et al. (2013). Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters. Annu. Rev. Pharmacol. Toxicol. 53 231–253. 10.1146/annurev-pharmtox-010611-134609 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chen Z. S., Lee K., Kruh G. D. (2001). Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 276 33747–33754. 10.1074/jbc.M104833200 [DOI] [PubMed] [Google Scholar]
  12. Cheng D., Ren J., Jackson E. K. (2010). Multidrug resistance protein 4 mediates cAMP efflux from rat preglomerular vascular smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 37 205–207. 10.1111/j.1440-1681.2009.05272.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chiavegatti T., Costa V. L., Araujo M. S., Godinho R. O. (2008). Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway. Br. J. Pharmacol. 153 1331–1340. 10.1038/sj.bjp.0707648 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Colgan S. P., Eltzschig H. K., Eckle T., Thompson L. F. (2006). Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2 351–360. 10.1007/s11302-005-5302-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cook W. H., Lipkin D., Markham R. (1957). The formation of a cyclic dianhydrodiadenylic acid (I) by the alkaline degradation of adenosine-5′-triphosphoric acid (II)1. J. Am. Chem. Soc. 79 3607–3608. 10.1021/ja01570a086 [DOI] [Google Scholar]
  16. Cordeaux Y., Briddon S. J., Alexander S. P., Kellam B., Hill S. J. (2008). Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. FASEB J. 22 850–860. 10.1096/fj.07-8180com [DOI] [PubMed] [Google Scholar]
  17. Cui X., Lee S. J., Kim S. Z., Kim S. H., Cho K. W. (2000). Effects of pituitary adenylate cyclase activating polypeptide27 on cyclic AMP efflux and atrial dynamics in perfused beating atria. Eur. J. Pharmacol. 402 129–137. 10.1016/S0014-2999(00)00514-8 [DOI] [PubMed] [Google Scholar]
  18. D’ Ambrosi N., Volonte C. (2013). Metabotropic purinergic receptors in lipid membrane microdomains. Curr. Med. Chem. 20 56–63. 10.2174/0929867311302010007 [DOI] [PubMed] [Google Scholar]
  19. de Koning H. P., Jenks B. G., Huchede B., Roubos E. W. (1992). Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis. Life Sci. 51 1667–1673. 10.1016/0024-3205(92)90311-C [DOI] [PubMed] [Google Scholar]
  20. Dessauer C. W. (2009). Adenylyl cyclase–A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol. Pharmacol. 76 935–941. 10.1124/mol.109.059345 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. DeWire S. M., Ahn S., Lefkowitz R. J., Shenoy S. K. (2007). Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69 483–510. 10.1146/annurev.physiol.69.022405.154749 [DOI] [PubMed] [Google Scholar]
  22. Doore B. J., Bashor M. M., Spitzer N., Mawe R. C., Saier M. H., Jr. (1975). Regulation of adenosine 3′ :5′-monophosphate efflux from rat glioma cells in culture∗. J. Biol. Chem. 250 4371–4372. [PubMed] [Google Scholar]
  23. Duarte T., Menezes-Rodrigues F. S., Godinho R. O. (2012). Contribution of the extracellular cAMP-adenosine pathway to dual coupling of beta2-adrenoceptors to Gs and Gi proteins in mouse skeletal muscle. J. Pharmacol. Exp. Ther. 341 820–828. 10.1124/jpet.112.192997 [DOI] [PubMed] [Google Scholar]
  24. Dubey R. K., Mi Z., Gillespie D. G., Jackson E. K. (1996). Cyclic AMP-adenosine pathway inhibits vascular smooth muscle cell growth. Hypertension 28 765–771. 10.1161/01.HYP.28.5.765 [DOI] [PubMed] [Google Scholar]
  25. Feoktistov I., Goldstein A. E., Biaggioni I. (1999). Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol. Pharmacol. 55 726–734. [PubMed] [Google Scholar]
  26. Francis S. H., Blount M. A., Corbin J. D. (2011). Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 91 651–690. 10.1152/physrev.00030.2010 [DOI] [PubMed] [Google Scholar]
  27. Fredholm B. B., IJzerman A. P., Jacobson K. A., Linden J., Muller C. E. (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update . Pharmacol. Rev. 63 1–34. 10.1124/pr.110.003285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Gao T., Puri T. S., Gerhardstein B. L., Chien A. J., Green R. D., Hosey M. M. (1997). Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes. J. Biol. Chem. 272 19401–19407. 10.1074/jbc.272.31.19401 [DOI] [PubMed] [Google Scholar]
  29. Garg V., Jiao J., Hu K. (2009). Regulation of ATP-sensitive K+ channels by caveolin-enriched microdomains in cardiac myocytes. Cardiovasc. Res. 82 51–58. 10.1093/cvr/cvp039 [DOI] [PubMed] [Google Scholar]
  30. Giron M. C., Bin A., Brun P., Etteri S., Bolego C., Florio C., et al. (2008). Cyclic AMP in rat ileum: evidence for the presence of an extracellular cyclic AMP-adenosine pathway. Gastroenterology 134 1116–1126. 10.1053/j.gastro.2008.01.030 [DOI] [PubMed] [Google Scholar]
  31. Gloerich M., Bos J. L. (2010). Epac: defining a new mechanism for cAMP action. Annu. Rev. Pharmacol. Toxicol. 50 355–375. 10.1146/annurev.pharmtox.010909.105714 [DOI] [PubMed] [Google Scholar]
  32. Godinho R. O., Costa V. L., Jr. (2003). Regulation of intracellular cyclic AMP in skeletal muscle cells involves the efflux of cyclic nucleotide to the extracellular compartment. Br. J. Pharmacol. 138 995–1003. 10.1038/sj.bjp.0705130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Grill V., Cerasi E., Wahren J. (1979). Role of cyclic AMP in glucagon-induced stimulation of hepatic glucose output in man. Scand. J. Clin. Lab. Invest. 39 689–696. 10.3109/00365517909108159 [DOI] [PubMed] [Google Scholar]
  34. Guo Y., Kotova E., Chen Z. S., Lee K., Hopper-Borge E., Belinsky M. G., et al. (2003). MRP8 ATP-binding cassette C11 (ABCC11), Is a cyclic nucleotide efflux pump and a resistance factor for Fluoropyrimidines 2′,3′-Dideoxycytidine and 9′-(2′-Phosphonylmethoxyethyl)adenine. J. Biol. Chem. 278 29509–29514. 10.1074/jbc.M304059200 [DOI] [PubMed] [Google Scholar]
  35. Hara Y., Sassi Y., Guibert C., Gambaryan N., Dorfmuller P., Eddahibi S., et al. (2011). Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J. Clin. Invest. 121 2888–2897. 10.1172/JCI45023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Headrick J. P., Ashton K. J., Rose’meyer R. B., Peart J. N. (2013). Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol. Ther. 140 92–111. 10.1016/j.pharmthera.2013.06.002 [DOI] [PubMed] [Google Scholar]
  37. Idzko M., Ferrari D., Eltzschig H. K. (2014a). Nucleotide signalling during inflammation. Nature 509 310–317. 10.1038/nature13085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Idzko M., Ferrari D., Riegel A. K., Eltzschig H. K. (2014b). Extracellular nucleotide and nucleoside signaling in vascular and blood disease. Blood 124 1029–1037. 10.1182/blood-2013-09-402560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Imura H., Matsukura S., Matsuyama H., Setsuda T., Miyake T. (1965). Adrenal steroidogenic effect of adenosine 3′,5′-monophosphate and its derivatives in vivo. Endocrinology 76 933–937. 10.1210/endo-76-5-933 [DOI] [PubMed] [Google Scholar]
  40. Jackson E. K., Mi Z., Gillespie D. G., Dubey R. K. (1997). Metabolism of cAMP to adenosine in the renal vasculature. J. Pharmacol. Exp. Ther. 283 177–182. [PubMed] [Google Scholar]
  41. Jackson E. K., Raghvendra D. K. (2004). The extracellular cyclic AMP-adenosine pathway in renal physiology. Ann. Rev. Physiol. 66 571–599. 10.1146/annurev.physiol.66.032102.111604 [DOI] [PubMed] [Google Scholar]
  42. Jedlitschky G., Burchell B., Keppler D. (2000). The Multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275 30069–30074. 10.1074/jbc.M005463200 [DOI] [PubMed] [Google Scholar]
  43. Jedlitschky G., Tirschmann K., Lubenow L. E., Nieuwenhuis H. K., Akkerman J. W., Greinacher A., et al. (2004). The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104 3603–3610. 10.1182/blood-2003-12-4330 [DOI] [PubMed] [Google Scholar]
  44. Kanter J. R., Hagey L. R., Brunton L. L. (1989). Inhibition of cyclic AMP efflux by insect pheromones and fatty acids. FEBS Lett. 244 149–153. 10.1016/0014-5793(89)81181-0 [DOI] [PubMed] [Google Scholar]
  45. Kruh G. D., Belinsky M. G. (2003). The MRP family of drug efflux pumps. Oncogene 22 7537–7552. 10.1038/sj.onc.1206953 [DOI] [PubMed] [Google Scholar]
  46. Laflamme M. A., Becker P. L. (1999). G(s) and adenylyl cyclase in transverse tubules of heart: implications for cAMP-dependent signaling. Am. J. Physiol. 277 H1841–H1848. [DOI] [PubMed] [Google Scholar]
  47. Larsson H. P. (2010). How is the heart rate regulated in the sinoatrial node? Another piece to the puzzle. J. Gen. Physiol. 136 237–241. 10.1085/jgp.201010506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Lasley R. D. (2011). Adenosine receptors and membrane microdomains. Biochim. Biophys. Acta 1808 1284–1289. 10.1016/j.bbamem.2010.09.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Levine R. A., Vogel J. A. (1966). Cardiovascular and metabolic effects of cyclic adenosine 3′, 5′-monophosphate in unanesthetized dogs. J. Pharmacol. Exp. Ther. 151 262–272. [PubMed] [Google Scholar]
  50. Li C., Krishnamurthy P. C., Penmatsa H., Marrs K. L., Wang X. Q., Zaccolo M., et al. (2007). Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131 940–951. 10.1016/j.cell.2007.09.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Menezes-Rodrigues F. S., Pires-Oliveira M., Duarte T., Paredes-Gamero E. J., Chiavegatti T., Godinho R. O. (2013). Calcium influx through L-type channels attenuates skeletal muscle contraction via inhibition of adenylyl cyclases. Eur. J. Pharmacol. 720 326–334. 10.1016/j.ejphar.2013.10.009 [DOI] [PubMed] [Google Scholar]
  52. Mi Z., Jackson E. K. (1998). Evidence for an endogenous cAMP-adenosine pathway in the rat kidney. J. Pharmacol. Exp. Ther. 287 926–930. [PubMed] [Google Scholar]
  53. Moreira I. S. (2014). Structural features of the G-protein/GPCR interactions. Biochim. Biophys. Acta 1840 16–33. 10.1016/j.bbagen.2013.08.027 [DOI] [PubMed] [Google Scholar]
  54. Muller C. E., Jacobson K. A. (2011). Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808 1290–1308. 10.1016/j.bbamem.2010.12.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Mundell S., Kelly E. (2011). Adenosine receptor desensitization and trafficking. Biochim. Biophys. Acta 1808 1319–1328. 10.1016/j.bbamem.2010.06.007 [DOI] [PubMed] [Google Scholar]
  56. O’Shaughnessy C., Poat J. A., Turnbull M. J. (1987). Cyclic AMP efflux from rat striatal slices is enhanced by CCK. Biochem. Pharmacol. 36 976–979. 10.1016/0006-2952(87)90196-1 [DOI] [PubMed] [Google Scholar]
  57. Osycka-Salut C., Diez F., Burdet J., Gervasi M. G., Franchi A., Bianciotti L. G., et al. (2014). Cyclic AMP efflux, via MRPs and A1 adenosine receptors, is critical for bovine sperm capacitation. Mol. Hum. Reprod. 20 89–99. 10.1093/molehr/gat053 [DOI] [PubMed] [Google Scholar]
  58. Pavan B., Capuzzo A., Forlani G. (2015). Quercetin and quercetin-3-O-glucoside interact with different components of the cAMP signaling cascade in human retinal pigment epithelial cells. Life Sci. 121 166–173. 10.1016/j.lfs.2014.11.010 [DOI] [PubMed] [Google Scholar]
  59. Pierce K. L., Premont R. T., Lefkowitz R. J. (2002). Signalling: seven-transmembrane receptors. Nat. Rev. Mol. Cell. Biol. 3 639–650. 10.1038/nrm908 [DOI] [PubMed] [Google Scholar]
  60. Plantie J. F., Mulder A. H., Stoof J. C. (1983). 3-PPP antagonizes the in vitro effects of D-1 and D-2 dopamine receptor agonists in rat neostriatum. Eur. J. Pharmacol. 91 317–320. 10.1016/0014-2999(83)90486-7 [DOI] [PubMed] [Google Scholar]
  61. Rall T. W., Sutherland E. W., Berthet J. (1957). The relationship of epinephrine and glucagon to liver phosphorylase: IV. Effect of epinephrine and glucagon on the reactivation of phosphorylase in liver homogenates . J. Biol. Chem. 224 463–475. [PubMed] [Google Scholar]
  62. Rasmussen H., Pechet M., Fast D. (1968). Effect of dibutyryl cyclic adenosine 3′,5′-monophosphate, theophylline, and other nucleotides upon calcium and phosphate metabolism. J. Clin. Invest. 47 1843–1850. 10.1172/JCI105874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Resta R., Yamashita Y., Thompson L. F. (1998). Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161 95–109. 10.1111/j.1600-065X.1998.tb01574.x [DOI] [PubMed] [Google Scholar]
  64. Ribeiro J. A., Sebastiao A. M., and de Mendon, a A. (2002). Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 68 377–392. 10.1016/S0301-0082(02)00155-7 [DOI] [PubMed] [Google Scholar]
  65. Rindler M. J., Bashor M. M., Spitzer N., Saier M. H., Jr. (1978). Regulation of adenosine 3′:5′-monophosphate efflux from animal cells. J. Biol. Chem. 253 5431–5436. [PubMed] [Google Scholar]
  66. Robison G. A., Butcher R. W., Oye I., Morgan H. E., and sutherland E. W. (1965). The effect of epinephrine on adenosine 3′, 5′-phosphate levels in the isolated perfused rat heart. Mol. Pharmacol. 1 168–177. [PubMed] [Google Scholar]
  67. Sadana R., Dessauer C. W. (2009). Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 17 5–22. 10.1159/000166277 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Sager G., Ravna A. W. (2009). Cellular efflux of cAMP and cGMP-a question about selectivity. Mini Rev. Med. Chem. 9 1009–1013. 10.2174/138955709788681654 [DOI] [PubMed] [Google Scholar]
  69. Sassi Y., Abi-Gerges A., Fauconnier J., Mougenot N., Reiken S., Haghighi K., et al. (2011). Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J. 26 1009–1017. 10.1096/fj.11-194027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Sassi Y., Ahles A., Truong D. J. J., Baqi Y., Lee S. Y., Husse B., et al. (2014). Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. J. Clin. Invest. 124 5385–5397. 10.1172/JCI74349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Sassi Y., Lipskaia L., Vandecasteele G., Nikolaev V. O., Hatem S. N., Cohen A. F., et al. (2008). Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J. Clin. Invest. 118 2747–2757. 10.1172/JCI35067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Schimmer B. P., Zimmerman A. E. (1976). Steroidogenesis and extracellular cAMP accumulation in adrenal tumor cell cultures. Mol. Cell. Endocrinol. 4 263–270. 10.1016/0303-7207(76)90060-5 [DOI] [PubMed] [Google Scholar]
  73. Schoffelmeer A. N., Hansen H. A., Stoof J. C., Mulder A. H. (1985). Inhibition of dopamine-stimulated cyclic AMP efflux from rat neostriatal slices by activation of mu- and delta-opioid receptors: a permissive role for D-2 dopamine receptors. Eur. J. Pharmacol. 118 363–366. 10.1016/0014-2999(85)90150-5 [DOI] [PubMed] [Google Scholar]
  74. Schoffelmeer A. N., Hogenboom F., Mulder A. H. (1988). M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 245 658–663. [PubMed] [Google Scholar]
  75. Schulte G., Fredholm B. B. (2003). Signalling from adenosine receptors to mitogen-activated protein kinases. Cell. Signal. 15 813–827. 10.1016/S0898-6568(03)00058-5 [DOI] [PubMed] [Google Scholar]
  76. Sciaraffia E., Riccomi A., Lindstedt R., Gesa V., Cirelli E., Patrizio M., et al. (2014). Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors. J. Biol. 96 113–122. 10.1189/jlb.3A0513-302RR [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Sellers Z. M., Naren A. P., Xiang Y., Best P. M. (2012). MRP4 and CFTR in the regulation of cAMP and β-adrenergic contraction in cardiac myocytes Eur. J. Pharmacol. 681 80–87. 10.1016/j.ejphar.2012.02.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Sheth S., Brito R., Mukherjea D., Rybak L. P., Ramkumar V. (2014). Adenosine receptors: expression, function and regulation. Int. J. Mol. Sci. 15 2024–2052. 10.3390/ijms15022024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Sitaraman S. V., Wang L., Wong M., Bruewer M., Hobert M., Yun C. H., et al. (2002). The adenosine 2b receptor is recruited to the plasma membrane and associates with E3KARP and Ezrin upon agonist stimulation. J. Biol. Chem. 277 33188–33195. 10.1074/jbc.M202522200 [DOI] [PubMed] [Google Scholar]
  80. Smoake J. A., McMahon K. L., Wright R. K., Solomon S. S. (1981). Hormonally sensitive cyclic AMP phosphodiesterase in liver cells. An ecto-enzyme . J. Biol. Chem. 256 8531–8535. [PubMed] [Google Scholar]
  81. Stangherlin A., Zaccolo M. (2011). Local termination of 3′-5′-cyclic adenosine monophosphate signals: the role of A kinase anchoring protein-tethered phosphodiesterases. J. Cardiovasc. Pharmacol. 58 345–353. 10.1097/FJC.0b013e3182214f2b [DOI] [PubMed] [Google Scholar]
  82. Stoof J. C., Kebabian J. W. (1981). Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294 366–368. 10.1038/294366a0 [DOI] [PubMed] [Google Scholar]
  83. Strouch M. B., Jackson E. K., Mi Z., Metes N. A., Carey G. B. (2005). Extracellular cyclic AMP-adenosine pathway in isolated adipocytes and adipose tissue. Obes. Res. 13 974–981. 10.1038/oby.2005.114 [DOI] [PubMed] [Google Scholar]
  84. Terrin A., Monterisi S., Stangherlin A., Zoccarato A., Koschinski A., Surdo N. C., et al. (2012). PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. J. Cell. Biol. 198 607–621. 10.1083/jcb.201201059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Trincavelli M. L., Daniele S., Martini C. (2010). Adenosine receptors: what we know and what we are learning. Curr. Top. Med. Chem. 10 860–877. 10.2174/156802610791268756 [DOI] [PubMed] [Google Scholar]
  86. Tyagi M. G., Handa R. K., Stephen P. M., Bapna J. S. (1998). Vasopressin induces dopamine release and cyclic AMP efflux from the brain of water-deprived rats: inhibitory effect of vasopressin V2 receptor-mediated phosphorylation. Biol. Signals Recept. 7 328–336. 10.1159/000014556 [DOI] [PubMed] [Google Scholar]
  87. Vallon V., Muhlbauer B., Osswald H. (2006). Adenosine and kidney function. Physiol. Rev. 86 901–940. 10.1152/physrev.00031.2005 [DOI] [PubMed] [Google Scholar]
  88. Ventimiglia M. S., Najenson A. C., Perazzo J. C., Carozzo A., Vatta M. S., Davio C. A., et al. (2015). Blockade of multidrug resistance associated proteins aggravates acute pancreatitis and blunts atrial natriuretic factor benefitial effect in rats: role of MRP4/ABCC4. Mol. Med. 10.2119/molmed.2014.00166 [Epub ahead of print]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Verrier J. D., Exo J. L., Jackson T. C., Ren J., Gillespie D. G., Dubey R. K., et al. (2011). Expression of the 2′,3′-cAMP-adenosine pathway in astrocytes and microglia. J. Neurochem. 118 979–987. 10.1111/j.1471-4159.2011.07392.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Walsh D. A., Perkins J. P., Krebs E. G. (1968). An adenosine 3′,5′-monophosphate-dependant protein kinase from rabbit skeletal muscle. J. Biol. Chem. 243 3763–3765. [PubMed] [Google Scholar]
  91. Wang J., Wu X., Simonavicius N., Tian H., Ling L. (2006). Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J. Biol. Chem. 281 34457–34464. 10.1074/jbc.M608019200 [DOI] [PubMed] [Google Scholar]
  92. Wei C. J., Li W., Chen J. F. (2011). Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim. Biophys. Acta 1808 1358–1379. 10.1016/j.bbamem.2010.12.018 [DOI] [PubMed] [Google Scholar]
  93. Woo Y. T., Manery J. F. (1973). Cyclic AMP phosphodiesterase activity at the external surface of intact skeletal muscles and stimulation of the enzyme by insulin. Arch. Biochem. Biophys. 154 510–519. 10.1016/0003-9861(73)90003-9 [DOI] [PubMed] [Google Scholar]
  94. Xie M., Rich T. C., Scheitrum C., Conti M., Richter W. (2011). Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP. Mol. Pharmacol. 80 281–293. 10.1124/mol.111.071134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Zaccolo M. (2009). cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br. J. Pharmacol. 158 50–60. 10.1111/j.1476-5381.2009.00185.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Zaccolo M., Magalhaes P., Pozzan T. (2002). Compartmentalisation of cAMP and Ca(2+) signals. Curr. Opin. Cell. Biol. 14 160–166. 10.1016/S0955-0674(02)00316-2 [DOI] [PubMed] [Google Scholar]
  97. Zimmermann H., Zebisch M., Strater N. (2012). Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 8 437–502. 10.1007/s11302-012-9309-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES